checkAd
    Orchestra BioMed Holdings Aktie
    6,9300
     
    USD
    +3,90 %
    +0,2600 USD
    Letzter Kurs 02:00:00 Nasdaq
    6,8900
     
    USD
    100 STK
    Geldkurs 31.05.24
    6,9300
     
    USD
    200 STK
    Briefkurs 31.05.24
    ISIN: US68572M1062 · WKN: A3D6DV · SYM: OBIO · USA

    Neueste Nachrichten

    Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
    22.05.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
    13.05.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
    30.04.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
    30.04.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
    27.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
    26.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
    13.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed to Participate in Upcoming Investor Conferences
    07.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
    06.03.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
    26.02.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
    08.01.24 · globenewswire · Orchestra BioMed Holdings
    Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
    13.11.23 · globenewswire · Orchestra BioMed Holdings